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Sir,
We read with interest the meta-analysis by Rowland et al addressing the
role of BRAF V600E mutation as predictor of benefit from anti-EGFR
monoclonal antibodies (mAbs) in metastatic colorectal cancer.
Authors conclude that there is insufficient evidence to definitively state that
RAS WT/BRAF MT individuals attain a reduced benefit from anti-EGFR mAbs
compared with RAS WT/BRAF WT ones. Their conclusion is based on the lack
of a significant interaction between BRAF mutational status and the effect of the
addition of an anti-EGFR mAb to standard therapies (Rowland et al, 2015).
In our opinion some considerations are needed to properly put these results
in the clinical perspective, as pointed out in our previous work (Pietrantonio
et al, 2015).
First, it should be noted that in terms of PFS, where the confounding effect of
subsequent lines of treatment is absent, the P-value for interaction is equal to
0.07. Of note, an alfa-error up to 0.10 is often considered reasonable for
interaction tests. In any case, it should be considered that these analyses are based
on the retrospective, unplanned evaluation of subgroups of patients included in
randomized trials and are therefore definitely underpowered to evidence a
statistically significant difference. Although the global number of patients
included in the analysis is high, the low incidence of BRAF V600E mutation
weakens the power of this analysis. In the meta-analysis, OS comparison
included 3096 patients (89% BRAF wild-type and 11% BRAF mutated). Even if
100% of events had been observed – that is a clear overestimation, especially with
respect to OS data – the statistical power to detect a significant interaction
between BRAF mutational status and the effect of anti-EGFR mAbs (assuming
hazard ratio 0.8 in BRAF wt and hazard ratio 1.0, that is, absence of effect, in
BRAF mutant patients) would have been as low as about 50%. Therefore, even if
the lack of statistical significance of the interaction test for OS is a matter of fact,
the relevant risk of a false negative result should be properly acknowledged.
Second, results from FIRE-3 trial, comparing first-line FOLFIRI plus
cetuximab with FOLFIRI plus bevacizumab were not included in
the metanalysis by Rowland et al. In their discussion, authors elegantly argue
that FIRE-3 is not sufficiently comparable to the other included trials, as
bevacizumab use in the control arm is associated with a significant benefit, as
compared with chemotherapy alone. We totally agree with that observation,
but, again, by a practical perspective it should be recognised that first-line
chemotherapy plus bevacizumab is one of the most common choices
worldwide. From a clinical point of view, the decision of adding an anti-
EGFR mAb to chemotherapy in patients with BRAF mutation, based on the
absence of interaction between BRAF status and treatment efficacy, would be
totally reasonable in the absence of therapeutic alternatives. Given that an
alternative is actually available, the use of an anti-EGFR mAb, instead of
bevacizumab, should be probably reserved to those patients who may actually
derive benefit from these drugs, with a different and often less acceptable
toxicity profile. To this purpose, the metanalysis by the same
authors highlighting the role of panRAS mutations as predictors of resistance
to anti-EGFR mAbs, also including results from FIRE-3, is of special interest
(Pietrantonio et al, 2015; Sorich et al, 2015). Unfortunately, results in the RAS
WT/BRAF WT subgroup of the FIRE-3 trial have not been provided yet, thus
preventing from including this trial in the present analysis. As information
about BRAF mutational status is also lacking from the other head-to-head
randomized trials PEAK and CALGB80409, we recognise that the question
about the ‘best’ biologic agent to be combined with a first-line chemotherapy
doublet in BRAF mutant individuals is far from being answered.
Third, as BRAF mutant patients are often unable to receive subsequent
lines of therapy (Seligmann et al, 2015), the choice of the upfront treatment
is of paramount importance. Although results with doublets plus a biologic
are disappointing (Stintzing et al, 2014), increasing evidences support the
choice of FOLFOXIRI plus bevacizumab as a preferred option for fit patients
(Fakih, 2015; Loupakis et al, 2014).
Nevertheless, more targeted approaches will hopefully enter the clinical
scenario in the next future, based on promising results of early phase trials
investigating BRAF ±MEK and EGFR inhibitors in molecularly selected
patients (Atreya et al, 2015). Knowing BRAF status is today crucial to allow
BRAF MT patients to enter clinical trials with those targeted agents.
In conclusion, although the negative predictive power of BRAF V600E
mutation with respect to anti-EGFR mAbs will never be formally demon-
strated in properly designed, wide and expensive clinical trials, BRAF testing is
today recommended by major guidelines. In our opinion, irrespectively of the
personal choice of treating physicians to expose BRAFmutant patients to anti-
EGFR mAbs, BRAF clearly stands as a molecular marker able to inform
clinical decisions in the daily practice, and hopefully its role in treatment
decisions will be better defined in the near future.
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Sir,
We thank Pietrantonio et al, for their interest in our recent manuscript
(Rowland et al, 2015). We also acknowledge their mutual interest in the field,
and share their goal of informing clinicians with the most accurate and
complete evidence to ensure that patients with metastatic colorectal cancer
(mCRC) are both afforded access and guided to the most appropriate
treatment interventions.
Pietrantonio et al, highlight that the power to detect differences in treatment
effect between subgroups based on BRAF mutation status is often poor, and
imply that the risk of false negative results is not properly acknowledged in this
manuscript. As described in the discussion section of the manuscript, we have
clearly and prominently addressed the issue of false positive and negative results
(Rowland et al, 2015). We believe that the evaluation of the predictive nature of
BRAF mutation for anti-EGFR therapy highlights what may be a relatively
common scenario in which it will be difficult to make definitive conclusions
despite having results from a number of high quality secondary analyses of
clinical trials. Factors contributing to the substantial risk of false positive or false
negative conclusions in this setting include (i) the post hoc nature of the analyses
and the associated difficulty in correcting for multiple hypotheses testing, (ii) the
biomarker having a low prevalence impacting on the precision of the estimates,
(iii) there being significant statistical heterogeneity (inconsistency) in results
between clinical studies, and (iv) that this biomarker may have a more modest
impact (e.g. attenuate than annul) on treatment efficacy compared to the
prominent biomarkers that have made their way into routine clinical practice
such as RAS mutations (Sorich et al, 2014).
Pietrantonio et al. highlight their own meta-analysis of anti-EGFR mAb
therapy in BRAF mutant tumours (Pietrantonio et al, 2015). This meta-analysis
concludes that ‘C- or P-based therapy did not increase the benefit of standard
therapy or the BSC in RAS-wt/BRAF-mut CRC patients.’ This meta-analysis
principally differs from ours on the basis of the methodology used to evaluate
whether BRAF is a predictive marker of anti-EGFR mAb efficacy. The evaluation
of heterogeneity of effect between subgroups by a test of interaction is the
standard approach recommended, on the basis that evaluating the efficacy of a
treatment with respect to an isolated subgroup is well known to have a high risk
of false positive results (i.e. falsely concluding that a subgroup has no effect)
(Rothwell, 2005; Kent et al, 2010; Sun et al, 2010). The Pietrantonio meta-analysis
only evaluated anti-EGFR efficacy in the BRAF mutant subgroup, whereas our
study compared the efficacy in the BRAF mutant subgroup to the subgroup
without a BRAF mutation (see (Altman and Matthews, 1996; Matthews and
Altman, 1996) for a simple introduction to the concept of interaction). With
respect to significance level, in our experience a stricter rather than more lenient
significance level is often preferred for making strong claims that will have
significant clinical and policy implications (as compared with exploratory/
screening questions). This is due to the post hoc nature of many subgroup
analyses and the inflated risks of false positives with multiple hypotheses testing
which are generally not explicitly adjusted for (Rothwell et al, 2005).
Our analysis highlight that the evidence for there being a treatment effect
difference between BRAF subgroups does not meet the conventional levels of
evidence when evaluated using the generally accepted approach for evaluating
subgroup differences in RCTs—hence our more moderate conclusion that there
currently is insufficient evidence to definitively state that there is a reduced (or no)
benefit for individuals with mutated BRAF. Cognizant of the risk of false negative
results, we have not ruled out the possibility that BRAF mutation status influences
anti-EGFR therapy efficacy, merely that the evidence does not support a definitive
claim that BRAF mutations does impact on efficacy. We advocate that as we can
neither definitively claim or rule out a predictive effect of a BRAF mutation that it
should remain at the clinician’s and patient’s discretion to decide whether to test
for BRAF mutation and whether use of an anti-EGFR mAb is appropriate for a
specific patient with a BRAF mutant tumor. We are concerned that the conclusion
of the Pietrantonio meta-analysis of no benefit for the BRAF mutant subgroup
may inadvertently lead to reduced clinician discretion to treat patients with BRAF
mutant tumours. For example, if the evidence clearly indicated that anti-EGFR
mAbs do not have benefit for patients with BRAF mutant tumours, then in many
jurisdictions this would lead payers to restrict subsidy of anti-EGFR mAbs to
individuals without a BRAF mutation (with routine testing for BRAF mutations).
We do not believe that the evidence currently available supports with sufficient
certainty that such individuals do not receive any benefit from anti-EGFR mAb
therapy.
We agree with Pietrantonio et al, that the trials comparing bevacizumab to
anti-EGFR mAb therapy are very informative in terms of guiding contemporary
first line therapy in mCRC and that when results stratified by BRAF mutations
status become available they will provide additional useful insight into the impact
of BRAF mutations on anti-EGFR mAb therapy. However, it will be important to
carefully manage how this data is analysed in conjunction with the data from
trials that evaluate the addition of anti-EGFR therapy to standard therapy (e.g.
focus on the difference between subgroups (Sorich et al, 2014)) as pooling results
from these different types of trials in a meta-analysis focusing only on the effect
size in the BRAF mutant subgroup may be misleading (Rowland et al, 2015).
On behalf of my colleagues
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